
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
An intelligent, on-premise platform connecting all the steps of your post-discovery routine qPCR workflows into one single ecosystem. Contact sales for a demo







